Qiming Venture Partners Portfolio Company Yunji Technology Debuts on Hong Kong Stock Exchange
In 2021, Qiming Venture Partners led the Series C round for Yunji Technology and continued to support the company's growth in subsequent funding rounds.
Swipe Left for the English Version
On October 16, Beijing time, Yunji Technology, a Qiming Venture Partners portfolio company and global leader in hospitality robotic-based AI agents, successfully listed on the Hong Kong Stock Exchange. Yunji Technology (02670.HK) priced its IPO at HK$95.6 per share and opened at HK$142.8 per share, reaching a market capitalization of HK$9.813 billion.
In 2021, Qiming Venture Partners led Yunji Technology's Series C round and continued to back the company through subsequent financing rounds.
Founded in 2014, Yunji Technology primarily provides customers with adaptive and scalable robots and functional kits, complemented by AI-powered digital systems. The company's core focus — hospitality robotic-based AI agents — refers to intelligent automation systems deployed on robots that integrate AI technology to deliver human-centric, end-to-end services through direct user interaction. Through continuous learning and adaptive optimization, these systems comprehensively elevate service quality and operational efficiency.
With leading products and technology, plus a streamlined and flexible integrated product-service offering, Yunji Technology's robotic AI agents have found wide application across diverse scenarios including hotels, factories, hospitals, and commercial buildings. To date, Yunji Technology has cumulatively deployed in 34,000 hotels worldwide. In 2024, the company's robots hit a peak of 36,000 units operating online in a single day, completing approximately 500 million service interactions over the full year. Most major hotel chains have selected Yunji Technology's robotic products as their first choice for intelligent upgrades, giving the company the top market share in China's hotel customer market — exceeding the combined total of the second- through fifth-ranked competitors.
"This IPO represents strong market validation of the commercial value of service robots, marking a critical step toward scaled deployment of robotic AI agents," said Tao Zhi, Founder, Chairwoman, and President of Yunji Technology. "Going forward, Yunji Technology will continue strengthening our full-stack R&D capabilities across both 'brain and limbs,' deepening our hotel-scene advantages while expanding into diverse commercial scenarios, attracting top global talent, and driving deeper integration between robotics technology and vertical industries — bringing intelligent services into every household."
Alex Zhou, Managing Partner of Qiming Venture Partners, said: "In 2021, Qiming recognized the maturation of indoor autonomous technology and made a decisive bet on high-demand scenarios like hotels. Since our investment, we've watched Yunji Technology deeply fuse technology with real-world applications, redefining the consumer experience through industry-leading robotic products. Looking ahead, this IPO will help power Yunji Technology's global market expansion, while emerging technologies like Embodied Artificial Intelligence will enable companies like Yunji to penetrate even richer scenarios. Qiming Venture Partners will leverage our global perspective and industrial ecosystem resources to support exceptional companies in extending their technological boundaries and commercial scenarios, bringing Chinese innovation to the world stage."
Qiming Venture Partners' Portfolio Company Yunji Technology Successfully Lists on the Hong Kong Stock Exchange
Yunji Technology, a global leader in the hospitality robotic-based AI agents market and a portfolio company of Qiming Venture Partners, has successfully debuted on the Hong Kong Stock Exchange on October 16th. Yunji Technology (SEHK:2670) was issued at HK$95.6 per share and opened at HK$142.8 per share, with a market capitalization of HK$9.81 billion.
Qiming led Yunji Technology's Series C funding round in 2021 and has continued to support the company's growth through subsequent financing round.
Founded in 2014, Yunji Technology offers adaptive and scalable robots and functional kits, complemented by services under AI digitalization system. The company primarily focuses on the development of hospitality robotic-based AI agents, intelligent and automated systems embodied on robots that integrate AI technologies to provide human-centric and end-to-end services when interacting directly with users. These agents enhance experiences and operational efficiency through continuous learning and adaptation.
Leveraging its robust products and technologies, along with a comprehensive product-service mix built for simplicity and flexibility, Yunji Technology's hospitality robotic-based AI agents are adaptable to diverse scenarios, including hotels, factories, hospitals, and buildings. To date, Yunji Technology has deployed its service robots in over 34,000 hotels worldwide. In 2024, the company's robots have reached a peak of 36,000 units operating online in a single day, completing approximately 500 million service interactions annually. Most major hotel chains have chosen Yunji Technology's robotic solutions as their first choice for intelligent upgrades, making the company the No. 1 player in China's hotel robotics market, with a market share larger than the combined total of the second to fifth competitors.
"This IPO is strong validation from the market of the commercial value of service robots, and it marks a critical milestone in our journey toward scaled deployment of hospitality robotic-based AI agents," said Tao Zhi, Founder, Chairwoman, and President of Yunji Technology. "Going forward, we'll continue strengthening our full-stack R&D capabilities in both brains and limbs, deepening our leadership in the hotel sector while expanding into new commercial verticals. We're committed to attracting world-class talent and driving deeper integration between robotics and industry-specific applications to bring intelligent services to households around the globe."
Alex Zhou, Managing Partner of Qiming Venture Partners, said, "In 2021, Qiming recognized the maturation of indoor autonomous technology and made strategic investments in high-demand markets such as the hotel sector. We have witnessed Yunji Technology effectively bridge technology and real-world applications, enhancing customer experiences through innovative robotic solutions. With this IPO, Yunji Technology is well-positioned to accelerate its expansion into global markets, while emerging technologies like embodied AI are expected to open new application opportunities. At Qiming, we remain committed to supporting exceptional companies by leveraging our global vision and industry resources, helping them push technological boundaries and deliver innovative solutions to international markets."
往期回顾
启明星 | 云迹科技完成C轮融资，启明创投领投 启明观点 | 启明创投周志峰：用投资的方式推动中国科技创新 启明荣誉 | 启明创投入选最科技T50——中国先锋科技投资机构50强榜单
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, Qiming has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Genrix Bio (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu, StepFun, Biren Technology, and others.